Evidence map›Paper›PMID 31603140›Full record

SynthesisAsian journal of andrology

The role of radical prostatectomy and definitive external beam radiotherapy in combined treatment for high-risk prostate cancer: a systematic review and meta-analysis.

Xu Cheng, Zhi-Hui Wang, Mou Peng, Zhi-Chao Huang, Lu Yi, Yi-Jian Li, Lei Yi, Wen-Zhi Luo, Jia-Wen Chen, Yin-Huai Wang

Abstract readComparative StudyMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Asian journal of andrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xu ChengDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Zhi-Hui WangT.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA.
Mou PengDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Zhi-Chao HuangDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Lu YiDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Yi-Jian LiDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Lei YiDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Wen-Zhi LuoDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Jia-Wen ChenDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Yin-Huai WangDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The first-line treatment options for high-risk prostate cancer (PCa) are definitive external beam radiotherapy (EBRT) with or without androgen deprivation therapy (ADT) and radical prostatectomy (RP) with or without adjuvant therapies. However, few randomized trials have compared the survival outcomes of these two treatments. To systematically evaluate the survival outcomes of high-risk PCa patients treated with EBRT- or RP-based therapy, a comprehensive and up-to-date meta-analysis was performed. A systematic online search was conducted for randomized or observational studies that investigated biochemical relapse-free survival (bRFS), cancer-specific survival (CSS), and/or overall survival (OS), in relation to the use of RP or EBRT in patients with high-risk PCa. The summary hazard ratios (HRs) were estimated under the random effects models. We identified heterogeneity between studies using Q tests and measured it using I

Indexed as

Androgen AntagonistsChemotherapy, AdjuvantDisease-Free SurvivalHumansMaleNeoplasm GradingProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiotherapyRadiotherapy, AdjuvantRiskSurvival RateAndrogen AntagonistsProstate-Specific Antigenhigh riskprostatectomyprostatic neoplasmsradiotherapysurvival

Identifiers

PMID31603140
PMCPMC7406105

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.